Lima, Peru — New information from the PURPOSE 2 research of twice-yearly lenacapavir for HIV prevention are among the many scientific highlights at HIVR4P 2024, the fifth HIV Analysis for Prevention Convention, happening in Lima, Peru, and nearly from 6 to 10 October.
On the official HIVR4P 2024 press convention at this time, PURPOSE 2 principal investigator Colleen Kelley of Emory College introduced new efficacy, security and demographic information from the trial, by which solely two HIV acquisitions occurred amongst 2,184 trial individuals who have been randomized to obtain subcutaneous lenacapavir each six months (for particulars, see the press launch issued at this time by Gilead Sciences, which developed lenacapavir). Kelley will formally current these information at HIVR4P 2024 on 8 October at a session beginning at 11:00 Peru time (PET).
PURPOSE 2 enrolled HIV-negative cisgender homosexual, bisexual and different males, trans ladies, trans males and gender non-binary people in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the USA who’ve intercourse with companions assigned male at delivery. Final month, topline outcomes from an interim evaluation indicated that lenacapavir diminished HIV acquisitions by 96% in comparison with background HIV incidence and demonstrated superiority to every day F/TDF for HIV prevention. Previous to that, the PURPOSE 1 research demonstrated that lenacapavir diminished HIV acquisitions by 100% and demonstrated superiority to every day F/TDF amongst cisgender ladies in Africa. Gilead Sciences has mentioned it should start a collection of world regulatory filings by the tip of 2024.
“These findings verify that lenacapavir for PrEP has the potential to remodel the worldwide HIV prevention panorama for folks of all genders,” Beatriz Grinsztejn, the President of IAS – the Worldwide AIDS Society – mentioned. “All stakeholders should work collectively now, forward of regulatory approvals, to plan for a speedy, equitable world rollout of this vital new prevention software.”
“The IAS commends Gilead for signing voluntary licensing agreements with generic producers to extend entry to lenacapavir in high-incidence, resource-limited international locations,” Grinsztejn added . “Nonetheless, we’re extremely involved that these agreements don’t cowl massive components of the world, together with the vast majority of international locations in Latin America.”
Grinsztejn can be a member of the PURPOSE 2 research group, an HIVR4P 2024 Organizing Committee member and the Director of the HIV/AIDS Scientific Analysis Unit on the Evandro Chagas Nationwide Institute of Infectious Ailments – FIOCRUZ in Brazil.
Different scientific highlights at HIVR4P 2024 embody:
• Proof that the three-month dapivirine vaginal ring is pharmacokinetically superior to the month-to-month ring
• A PrEP selection research discovering average uptake of the dapivirine vaginal ring amongst ladies in Africa
• A research discovering no pharmacologic interactions between long-acting cabotegravir for HIV prevention and hormonal contraceptives
• A drug-agnostic transcutaneously refillable subdermal implant that gives ultra-long-acting supply of antiretrovirals for HIV prevention
• Knowledge exhibiting that an revolutionary dosing technique improves early immune responses to an experimental germline-targeting HIV vaccine
Hosted by the IAS, HIVR4P is the one world scientific convention centered solely on the quickly evolving discipline of HIV prevention analysis. It brings collectively the worldwide scientific neighborhood to deal with the most important challenges and alternatives in HIV prevention, together with vaccines, microbicides, PrEP, remedy as prevention, and biomedical interventions, in addition to the social and behavioural implications of those advances.
This 12 months, the convention is being held in Latin America for the primary time, creating a chance to spotlight HIV prevention wants within the area.
“We hope that by holding the convention in Lima, we may also help draw consideration to the pressing must scale up HIV prevention efforts throughout Latin America,” Grinsztejn mentioned. “Ours is among the solely areas on the planet the place HIV is on the rise. It’s alarming that new HIV acquisitions in Latin America elevated by 9% between 2010 and 2023 regardless of broadly expanded entry to antiretroviral remedy. Sadly, the dimensions of highly effective new prevention instruments like PrEP stays considerably restricted.”
